Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...this would have been my predicted XL-20%
*** (c)LI-portfolio 0815ax (BigBoards) 05(update)/2009 ***
ACAS - CENX - CTIC * - CPE - EMKR - FITB * - GNW - HGSI - HIG - KV.A
MTG * - NEXM - PLD * - PWAV - RZ - STP - SRZ - XL - XTXI * - YGE
* ~ "free shares"
*** (c)LI-portfolio 0815ax (OTCBB) 05/2009 ***
GNPH - NEOM
*** (c)(Q)-portfolio 0815ax (Chapter11) 05/2009 ***
CEMJQ - LEHMQ - SSCCQ - WAMUQ
MTG now "FREE Shares"
Bernstein raises Fifth Third Bancorp to outperform
http://www.finanznachrichten.de/nachrichten-2009-05/13856192-brief-bernstein-raises-fifth-third-bancorp-to-outperform-020.htm
08.05.2009 13:33
May 8 (Reuters) -
* Bernstein raises Fifth Third Bancorp (News) to outperform from market perform
* Bernstein raises Fifth Third Bancorp price target to $9 from $4
OPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
CTIC -
http://seekingalpha.com/article/136399-cell-therapeutics-turnaround-remains-on-track?source=feed
Cell Therapeutics' Turnaround Remains on Track
by: Mike Havrilla May 08, 2009
The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results Thursday, which included a 76% reduction of net loss and expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed or is refractory to standard treatment options.
CTIC achivied its objective thus far during 1H09, including the initiation of the rolling NDA submission for pixantrone, reducing net loss through cost cutting initiatives, raising gross proceeds of $44.3M, and cleaning up the Company's capital structure through the elimination of all previously issued preferred stock. CTIC is on target to complete the pixantrone NDA filing by June and if the FDA grants a priority revew, the Company could receive an approval decision before year-end in December.
The Company riased $23.8M through the sale of newly-issued preferred stock to a single institutional investor and the exercise of common stock warrants associated with the transaction. All shares of preferred stock in the deal were subsequently converted into common stock by the investor so that CTIC has no preferred stock outstanding at this time. CTIC received $20.5M in gross proceeds earlier this year from Spectrum Pharma (SPPI) as part of the sale of its 50% stake in their previous joint venture to market cancer drug Zevalin.
CTIC reduced its total net operating expenses by $21.8M to $6.6M for 1Q09, compared to $28.4M in the year-ago period due to the $10.2M one-time gain on the Zevalin joint venture sale along with a decline in R&D spending (down by 50% to $8M versus the year-ago period). Excluding the one-time gain, operating expenses still decreased by 41% from the year-ago period. The net loss attributable to common shareholders decreased by 76% or $41.5M to $13.1M or $0.05 per share, compared to $54.6M or $7.68 per share in the year-ago period.
!!! HIG !!!
FITB now "FREE Shares"
(my PLI-target: $xx.00]
added GCI ( GANNETT CO INC )
http://us.rd.yahoo.com/finance/external/cnbc/SIG=11h64n478/*http%3A//www.cnbc.com/id/30579871/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo
Biggest Shorts on the S&P 500
Published: Tuesday, 5 May 2009 | 11:47 AM ET
SEC Chair, Mary Schapiro, announced that she has made it a priority to evaluate regulations on short selling.
http://media.cnbc.com/i/CNBC/Sections/News_And_Analysis/_Blogs/By_The_Numbers/__DAILY%20POSTS/090505%20Shorts.gif
Last month the SEC put forth 5 alternative plans for rules on short selling. Options being considered range from the uptick rule to the ban of short selling for stocks that fall more than 10% in a trading session.
During the market turmoil last fall, many financial stocks were targeted by short sellers. The SEC instituted an unprecedented ban on the short selling of 870 US companies until the TARP was instituted.
>>> Trends in Shorts in Financials
Depending on how things move within the SEC, the companies with sizable short positions, may see a lift as short sellers get squeezed and are forced to buy back shares they sold.
Data source: Thomson Reuters
http://shortsqueeze.com/?symbol=gci&submit=Short+Quote%99
Shares Float 227,930,000
Total Shares Outstanding 228,409,277
% Owned by Insiders 22.36 %
% Owned by Institutions 96.20 %
? how many do you have (0815ax: 700)
!!! GNPH !!!
CTIC now "FREE Shares"
(my PLI-target: $xx.00]
?? you sure that this is "bounced out" ?
Tenet Reports Results for First Quarter Ended March 31, 2009
http://www.finanznachrichten.de/nachrichten-2009-05/13815355-tenet-reports-results-for-first-quarter-ended-march-31-2009-004.htm
05.05.2009 13:38
Tenet Reports Results for First Quarter Ended March 31, 2009
Highlights:
$276 million in total adjusted EBITDA, an increase of 28.4 percent; $273 million in same-hospital adjusted EBITDA, an increase of 25.8 percent
Net income attributable to shareholders of $178 million, an increase of $209 million
Reduced cash consumption by $151 million, or 52.8 percent: $135 million use of cash in adjusted free cash flow from continuing operations; net cash used in operating activities was $6 million in the first quarter of 2009 compared to $133 million in the first quarter of 2008
$652 million in cash and equivalents at Mar. 31, 2009, an increase of $145 million from Dec. 31, 2008
1.3 percent decrease in same-hospital paying admissions, approximately 0.1 percent decrease after adjusting for the extra weekday in 2008’s first quarter due to Leap Year
1.3 percent decrease in same-hospital total admissions, approximately 0.1 percent decrease adjusted for Leap Year
2.3 percent increase in same-hospital paying outpatient visits, approximately 3.4 percent increase adjusted for Leap Year
0.7 percent increase in total same-hospital outpatient visits, approximately 1.8 percent increase adjusted for Leap Year
2.6 percent increase in same-hospital total surgeries, approximately 3.7 percent adjusted for Leap Year
4.7 percent increase in same-hospital outpatient surgeries, approximately 5.8 percent increase adjusted for Leap Year
3.2 percent decrease in same-hospital commercial managed care admissions, approximately 2.0 percent decrease adjusted for Leap Year
1.5 percent decrease in same-hospital commercial managed care outpatient visits, approximately 0.4 percent decrease adjusted for Leap Year
4.5 percent increase in same-hospital commercial managed care revenues
$101 million in capital expenditures in continuing operations
Bad debt ratio of 6.8 percent of net revenues, an increase of 10 basis points from 6.7 percent in Q1’08
...
CTIC - Pixantrone Now Available in Europe
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37542379
CTIC - Pixantrone Now Available in Europe
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37542379
CTIC - Pixantrone Now Available in Europe
05.05.2009 07:31
Pixantrone Now Available in Europe on a Named-Patient Basis / Cell Therapeutics and IDIS Partner to Accelerate Patient Access to Pixantrone through Program
http://www.finanznachrichten.de/nachrichten-2009-05/13810314-pixantrone-now-available-in-europe-on-a-named-patient-basis-cell-therapeutics-and-idis-partner-to-accelerate-patient-access-to-pixantrone-through-pr-008.htm
SEATTLE, May 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (News) (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed after standard therapies or is refractory to them. We know of no therapy that has previously been shown to be effective treatment for such patients.
"CTI has worked hard to make pixantrone available in Europe at the prescriber's request as it provides an option for these difficult to treat aggressive NHL patients," noted Craig Philips, President of CTI. "We continue to work toward potential approval of pixantrone at the end of 2009 in the United States and expect to complete the submission of the New Drug Application to the Food&Drug Administration this quarter."
"Our experience with pixantrone has been positive with patients achieving a complete response where such a result was not achievable with other treatments," said Prof. Pier Luigi Zinzani, M.D., Institute of Hematology and Oncology, University of Bologna. "I am pleased that it is now available on a named-patient basis as it has the potential to address a significant unmet need in this heavily pretreated patient population."
A named-patient program is a compassionate use drug supply program under which physicians can legally supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs can be administered to patients who are suffering from serious illnesses prior to the drug being approved by the European Medicines Evaluation Agency. "Named-patient" distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient. In Europe, under the named-patient program the drug is most often purchased through the national health system.
Contact Information for Program:
Licensed healthcare professionals in Europe treating individual patients with relapsing or refractory aggressive non-Hodgkin's lymphoma interested in pixantrone should contact:
IDIS Limited
Tel: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: internationalsales@idispharma.com
Additionally, more information can be found at
http://www.celltherapeutics.com/pixantrone_europe
About Pixantrone
Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.
About IDIS
IDIS is the world leader in the development and implementation of named-patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. IDIS supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide. For more information on IDIS please visit their website at http://www.idispharma.com/.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the results of complete safety information, the failure to receive anticipated number of requests for pixantrone to treat specific patients, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the New Drug Application submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
http://www.celltherapeutics.com/press_room
Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
E: invest@ctiseattle.com
http://www.celltherapeutics.com/investors
Cell Therapeutics, Inc.
CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
media@ctiseattle.com, or Investors, Ed Bell, +1-206-272-4345, or Lindsey Jesch
Logan, +1-206-272-4347, fax, +1-206-272-4434, invest@ctiseattle.com, all of
Cell Therapeutics, Inc.
Web Site: http://www.celltherapeutics.com/
... FITB HIG STP ...
- What a day! -
Chapter 11 - P(Q)LI : added SSCCQ + CEMJQ
Sunrise Announces Overhead Downsizing Plan
http://ih.advfn.com/p.php?pid=nmona&cb=1241447887&article=37550042&symbol=NY%5ESRZ
Expects to Achieve $20 Million of Annual Recurring Savings through Further Cost Reductions
MCLEAN, Va., May 4 /PRNewswire-FirstCall/ -- Sunrise Senior Living, Inc. (NYSE:SRZ) today announced details of its efforts to reduce overhead spending and become a leaner organization. Sunrise expects to realize more than $20 million of annual recurring savings from a reduction in non-care related administrative costs. In connection with this announcement, Richard J. Nadeau, Sunrise's chief financial officer, will transition from his role on or before June 15, 2009, at which time Julie A. Pangelinan, Sunrise's chief accounting officer, will succeed Mr. Nadeau as chief financial officer of Sunrise.
"We continue to work on a number of fronts to strengthen the financial position of Sunrise," said Mark Ordan, Sunrise's chief executive officer. "The decision to reduce the number of people at Sunrise is never easy, but it was essential given today's economic environment and our need to further reduce spending. We want to be completely clear that none of these changes will affect the extraordinary care and services we provide in our communities."
Overhead Downsizing
The Company's plan for downsizing its overhead is designed to reduce non-care related corporate expenses by reorganizing Sunrise's corporate cost structure, including through a reduction in spending related to administrative processes, vendors and consultants. Sunrise expects the plan will reduce the Company's annual recurring general and administrative expenses by more than $20 million, from the 2009 budgeted annual recurring level of approximately $120 million to approximately $100 million, and to reduce the Company's centrally administered services, which are charged to the communities, by approximately $1.5 million.
Sunrise has identified at least 150 positions to be eliminated at its corporate headquarters, in Germany, and in Sunrise's regional support group (costs above the community level). Sunrise currently expects to record additional severance expense of approximately $4.5 million in 2009 as a result of this plan, which is expected to be completed by early 2010.
CFO Transition
As part of the Sunrise's overhead downsizing plan, Mr. Nadeau's employment with Sunrise will be terminated effective on or before June 15, 2009, and, at that time, Ms. Pangelinan, Sunrise's chief accounting officer, will be promoted to chief financial officer and lead Sunrise's finance team. Mr. Nadeau's departure was based on mutual agreement and accordingly is pursuant to the "other than for cause" clause under his employment agreement with Sunrise.
"This is a win-win. I have worked with Rick throughout my Sunrise term and before, and we are all grateful for all he has done to help put Sunrise on a better path," said Mr. Ordan. "We are all very fortunate that we can continue to rely on the proven skills and leadership of Julie Pangelinan and her management team."
Ms. Pangelinan joined Sunrise as chief accounting officer in April 2006. Prior to joining Sunrise, Ms. Pangelinan worked for Marriott International, Inc. as vice president, accounting policy, from April 2003 to April 2006 and as senior director of accounting policy from August 2000 to May 2003, where Ms. Pangelinan was responsible for providing proactive leadership on accounting policy for business transactions and deal structures, as well as managing all external financial reporting and regulatory filings, and ensuring compliance with the rules of the U.S. Securities and Exchange Commission and generally accepted accounting principles. Prior to working at Marriott International, Inc., Ms. Pangelinan was an audit partner at BDO Seidman, LLP.
Further details concerning the overhead downsizing plan and CFO transition will be contained in a Form 8-K to be filed by Sunrise today with the U.S. Securities and Exchange Commission.
Economic Calendar (May 4 - May 8)
http://www.bloomberg.com/markets/ecalendar/index.html
nice! ...and boardmarks up to 161! this morning
PLI currently #1 - Top15 Trader Forums
LOL
work on ibox terminated...
WAMUQ -
confirmed "Chapter 11 - P(Q)LI" on Promising Longterm Investments - board
http://investorshub.advfn.com/boards/board.aspx?board_id=11828
Sunrise to Host Conference Call and Webcast to Discuss First-Quarter 2009 Financial Results
http://phx.corporate-ir.net/phoenix.zhtml?c=115860&p=irol-newsArticle&ID=1283416&highlight=
MCLEAN, Va., May 1 /PRNewswire-FirstCall/ -- Sunrise Senior Living, Inc. (NYSE: SRZ) today announced that it will host a conference call and Webcast on Friday, May 8, 2009, at 9 a.m. ET to discuss its financial results for the first-quarter 2009. Mark Ordan, chief executive officer, Richard Nadeau, chief financial officer, and Julie Pangelinan, chief accounting officer, will host the call.
The call-in number for the conference call is 877-719-9796 or 719-325-4827 (from outside the U.S.). Callers should reference the "Sunrise Senior Living Q1 Earnings Call" or the participant passcode: 1059514. Those interested may also go to the Investor Relations section of the Company's Web site (http://www.sunriseseniorliving.com) to listen to the earnings call. A telephone replay of the call will be available until May 22 at 12 p.m. ET, by dialing 888-203-1112 or 719-457-0820 (passcode: 1059514); a replay will also be available on Sunrise's Web site during that period.
About Sunrise Senior Living
Sunrise Senior Living, a McLean, Va.-based Company, employs approximately 40,000 people. As of December 31, 2008, Sunrise operated 435 communities in the United States, Canada, Germany and the United Kingdom, with a combined capacity for approximately 54,000 residents. Sunrise offers a full range of personalized senior living services, including independent living, assisted living, care for individuals with Alzheimer's and other forms of memory loss, as well as nursing, rehabilitative and hospice care. Sunrise's senior living services are delivered by staff trained to encourage the independence, preserve the dignity, enable freedom of choice and protect the privacy of residents. To learn more about Sunrise, please visit http://www.sunriseseniorliving.com.
ACAS -
http://shortsqueeze.com/?symbol=acas&submit=Short+Quote%99
Shares Float 200,680,000
Total Shares Outstanding 204,726,614
% Owned by Insiders 1.06 %
% Owned by Institutions 38.40 %
Historical Prices (Dividend)
http://finance.yahoo.com/q/hp?s=ACAS&a=08&b=2&c=1997&d=04&e=2&f=2009&g=v
Analyst Estimates (Current Qtr.Mar-09: 0.37)
http://finance.yahoo.com/q/ae?s=ACAS
Q1/09 - ACAS Receives Cash Proceeds of $22 Million from Sale of Corrpro Companies
http://www.finanznachrichten.de/nachrichten-2009-04/13626151-american-capital-receives-cash-proceeds-of-dollar-22-million-from-sale-of-corrpro-companies-008.htm
14.04.2009 21:50
American Capital Receives Cash Proceeds of $22 Million from Sale of Corrpro Companies
BETHESDA, Md., April 14 /PRNewswire-FirstCall/ -- American Capital Ltd. (News) announced today that in the first quarter of 2009 it received cash proceeds of $22 million from the sale of its portfolio company Corrpro Companies Inc. to a wholly-owned subsidiary of Insituform Technologies Inc. , realizing a gain of $6 million. Including investments in Corrpro by American Capital's affiliated funds under management, total inception to date realized gains and dividends received were $9 million. American Capital's compounded annual rate of return, including interest, dividends and fees earned over the life of its investment was 21%. The proceeds received by American Capital were greater than the fourth quarter 2008 valuation of the investment by $0.5 million, or 2%.
In March 2004, American Capital invested $16 million in Corrpro to support its recapitalization by Wingate Partners. American Capital's investment took the form of senior subordinated debt with warrants and redeemable preferred equity with warrants.
"It has been a pleasure to partner with Wingate for the first time on our investment in Corrpro," said Douglas Kelley, Principal, Sponsor Finance Group. "Over the course of our five year investment, Corrpro made strategic investments in marketing and personnel, which were critical in growing revenue and cash flow. We commend management on making the right investments in attractive market segments, which generated attractive returns for all company stakeholders, including American Capital."
Corrpro, headquartered in Medina, Ohio and Houston, Texas, with over 30 offices worldwide, is a leading provider of corrosion control engineering services, systems and equipment to the infrastructure, environmental and energy markets around the world. Corrpro is the leading provider of cathodic protection systems and engineering services, as well as corrosion protection services relating to coatings, pipeline integrity and reinforced concrete structures.
Since American Capital's August 1997 IPO through the fourth quarter of 2008, the company has earned a 17% compounded annual return, including interest, dividends, fees and net gains, on 249 realizations of senior debt, subordinated debt and equity investments, totaling $11 billion of committed capital. These realizations represent 47% of all amounts invested by American Capital since its August 1997 IPO. Proceeds from these realizations exceeded the total associated prior quarter valuation of the investments by less than 1%. American Capital earned a 30% compounded annual return on the exit of its equity investments, including dividends, fees and net gains.
For more information about American Capital's investment in Corrpro, please go to http://www.americancapital.com/news/newsreleases/2004/pr20040331.html.
For a chart showing American Capital's exited portfolio companies, please go to http://www.americancapital.com/our_portfolio/exited.html.
ABOUT AMERICAN CAPITAL
American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. Founded in 1986, American Capital has $14 billion(1) in capital resources under management and ten offices in the U.S., Europe and Asia. For further information, please refer to http://www.americancapital.com/.
(1)As of December 31, 2008.
Performance data quoted above represents past performance of American Capital. Past performance does not guarantee future results and the investment return and principal value of an investment in American Capital will likely fluctuate. Consequently, an investor's shares, when sold, may be worth more or less than their original cost. Additionally, American Capital's current performance may be lower or higher than the performance data quoted above.
This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions, or changes in the conditions of the industries in which American Capital has made investments.
CONTACT: Douglas Kelley, Principal, Sponsor Finance Group (214) 273-6655 Jennifer Burke, Corporate Communications (301) 968-9400
American Capital Ltd.
CONTACT: Douglas Kelley, Principal, Sponsor Finance Group,
+1-214-273-6655, or Jennifer Burke, Corporate Communications of American
Capital Ltd., +1-301-968-9400
Web Site: http://www.americancapital.com/
American Capital Will Report Q1 2009 Results on May 5
http://www.finanznachrichten.de/nachrichten-2009-04/13716373-american-capital-will-report-q1-2009-results-on-may-5-shareholder-call-scheduled-for-may-6-008.htm
23.04.2009 22:03
American Capital Will Report Q1 2009 Results on May 5 / Shareholder Call Scheduled for May 6
BETHESDA, Md., April 23 /PRNewswire-FirstCall/ -- American Capital Ltd. (News) announced today that it will report first quarter 2009 earnings after market close on May 5, 2009. Shareholders, prospective shareholders and analysts may listen to the shareholder call on May 6 at 11:00 am ET via a free live webcast at http://www.americancapital.com/ or by dialing (866) 269-9612 (U.S. domestic) or +1 (612) 288-0329 (international). Please advise the operator you are dialing in for the American Capital shareholder call.
An archived audio of the call combined with the slide presentation will be made available on our website after the call. In addition, there will be a phone recording available from 3:00 pm May 6 until 11:59 pm May 20. If you are interested in hearing the recording of the presentation, please access it for free on our website or dial (800) 475-6701 (U.S. domestic) or +1 (320) 365-3844 (international). The access code for both domestic and international callers is 996586.
For further information or questions, please do not hesitate to call our Investor Relations Department at (301) 951-5917 or send an email to IR@AmericanCapital.com.
ABOUT AMERICAN CAPITAL
American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. Founded in 1986, American Capital has $14 billion(1) in capital resources under management and ten offices in the U.S., Europe and Asia. For further information, please refer to http://www.americancapital.com/.
(1) As of December 31, 2008.
Performance data quoted above represents past performance of American Capital. Past performance does not guarantee future results and the investment return and principal value of an investment in American Capital will likely fluctuate. Consequently, an investor's shares, when sold, may be worth more or less than their original cost. Additionally, American Capital's current performance may be lower or higher than the performance data quoted above.
This press release contains forward-looking statements. The statements regarding expected results of American Capital are subject to various factors and uncertainties, including the uncertainties associated with the timing of transaction closings, changes in interest rates, availability of transactions, changes in regional, national or international economic conditions or changes in the conditions of the industries in which American Capital has made investments.
Contact: Investors - (301) 951-5917
American Capital, Ltd.
CONTACT: Investors, American Capital, +1-301-951-5917
Web Site: http://www.americancapital.com/
Sec Filings Insider Trading - American Capital Ltd. (ACAS)
http://www.secform4.com/insider-trading/817473.htm
Statement of Changes in Beneficial Ownership
04/30/2009 http://ih.advfn.com/p.php?pid=nmona&cb=1241284769&article=37514618&symbol=NY%5ESRZ
05/01/2009 http://ih.advfn.com/p.php?pid=nmona&cb=1241284769&article=37539025&symbol=NY%5ESRZ
...will redesign ibox next week, think then we will have such picture
...if there is a significant breakout during next week(s), then YES, will watching it...